Last updated: August 14, 2026
Durvalumab, marketed by AstraZeneca as Imfinzi, is one of the leading PD-L1 checkpoint inhibitors. Its commercial trajectory has shifted from a narrow urothelial-cancer product to a broad oncology platform spanning lung cancer, biliary tract cancer, hepatocellular carcinoma, and other solid tumors. AstraZeneca reported Imfinzi sales of approximately $4.2 billion in 2023, with continued growth driven by first-line lung-cancer use, extensive-stage small-cell lung cancer, and new perioperative and combination regimens.[1]
The main commercial risks are intense competition from pembrolizumab and nivolumab, pricing pressure from combination immunotherapy, loss of exclusivity in the early 2030s, and the need to produce additional survival benefits in crowded treatment settings.
What is durvalumab and how does AstraZeneca market Imfinzi?
Durvalumab is a fully human monoclonal antibody that binds programmed death ligand 1, or PD-L1. The drug blocks PD-L1 interaction with PD-1 and CD80, allowing T-cell activity against tumor cells.
| Attribute |
Durvalumab |
| Brand |
Imfinzi |
| Active ingredient |
Durvalumab |
| Developer |
MedImmune, acquired by AstraZeneca |
| Sponsor |
AstraZeneca |
| FDA regulatory route |
Biologics license application |
| U.S. BLA |
BLA 761069 |
| Mechanism |
PD-L1 checkpoint inhibition |
| Initial FDA approval |
May 1, 2017 |
| Principal delivery |
Intravenous infusion |
| Core commercial areas |
NSCLC, SCLC, biliary tract cancer, HCC |
| Main competitors |
Pembrolizumab, nivolumab, atezolizumab, cemiplimab |
Imfinzi is generally administered by intravenous infusion, either as monotherapy or with chemotherapy, tremelimumab, or other systemic treatment. AstraZeneca has positioned durvalumab around disease settings in which treatment duration, curative-intent therapy, and combination use can support durable revenue.
What indications drive durvalumab sales?
Lung cancer is the primary commercial engine for durvalumab. The drug's strongest established position is unresectable stage III non-small-cell lung cancer after concurrent platinum-based chemoradiotherapy, where consolidation treatment is intended to delay progression and improve survival.
Key FDA-approved or commercially relevant uses
| Disease setting |
Durvalumab role |
Commercial significance |
| Unresectable stage III NSCLC |
Consolidation after chemoradiotherapy |
Established standard-of-care segment |
| Extensive-stage SCLC |
First-line combination with platinum chemotherapy and etoposide |
Large recurring treatment population |
| Limited-stage SCLC |
Consolidation after chemoradiotherapy in eligible patients |
Expands curative-intent lung franchise |
| Advanced biliary tract cancer |
Combination with gemcitabine and cisplatin |
Important non-lung growth driver |
| Unresectable or metastatic HCC |
Combination with tremelimumab |
Supports dual-checkpoint franchise |
| Metastatic NSCLC |
Combination with tremelimumab and chemotherapy in selected settings |
Competes with pembrolizumab-led regimens |
The PACIFIC trial established durvalumab in stage III NSCLC, while the CASPIAN trial supported its use in extensive-stage SCLC.[2,3] TOPAZ-1 expanded the product into biliary tract cancer, a smaller market with limited historical treatment options.[4] HIMALAYA supported the durvalumab-tremelimumab regimen in advanced HCC.[5]
The ADRIATIC program further expanded the strategic opportunity in limited-stage SCLC. FDA approval in late 2024 created a second major curative-intent lung-cancer use after stage III NSCLC.[6]
How has durvalumab revenue changed?
AstraZeneca reports Imfinzi sales as a product-level figure. The company does not separately disclose revenue for each indication, dosing regimen, geographic market, or combination partner.
| Year |
Imfinzi revenue |
Commercial interpretation |
| 2018 |
Approximately $0.7 billion |
Early launch and NSCLC uptake |
| 2019 |
Approximately $1.4 billion |
PACIFIC adoption accelerated |
| 2020 |
Approximately $1.7 billion |
Lung franchise expanded despite pandemic disruption |
| 2021 |
Approximately $2.4 billion |
SCLC and broader international uptake |
| 2022 |
Approximately $3.0 billion |
Biliary tract and HCC contributions began |
| 2023 |
Approximately $4.2 billion |
Strong growth across lung and non-lung indications |
Sources: AstraZeneca annual reports and financial releases.[1,7]
Imfinzi's revenue growth has outpaced the growth of the original stage III NSCLC indication because AstraZeneca added new treatment lines and tumor types. The commercial model now depends on three revenue layers:
- Maintenance or consolidation treatment in lung cancer.
- Combination therapy in first-line extensive-stage SCLC and biliary tract cancer.
- Dual-checkpoint use with tremelimumab in HCC and selected NSCLC settings.
AstraZeneca's reported results indicate that Imfinzi became a multibillion-dollar product before the company faced meaningful U.S. biosimilar competition. The next phase of growth depends less on initial approval and more on perioperative, limited-stage, and earlier-line treatment.
What is the market outlook for durvalumab?
The near-term market outlook is positive but increasingly competitive. The addressable market is large because checkpoint inhibitors are used across high-incidence cancers, but treatment selection is governed by tumor type, biomarker status, prior therapy, chemotherapy eligibility, and reimbursement.
Growth drivers
- Continued penetration in extensive-stage SCLC.
- Adoption in biliary tract cancer after TOPAZ-1.
- Expansion into limited-stage SCLC after ADRIATIC.
- Use in earlier-stage and curative-intent treatment.
- Growth in China and other international markets.
- Combination regimens that increase treatment value per patient.
- Potential use in additional perioperative or neoadjuvant settings.
Market constraints
- Pembrolizumab has broader labeling and a larger installed base.
- Nivolumab is entrenched in several thoracic and gastrointestinal indications.
- Atezolizumab competes directly in lung and liver cancer.
- Combination regimens increase toxicity, infusion burden, and payer scrutiny.
- PD-L1 expression and tumor biology limit universal use.
- Some markets require health-economic justification for prolonged therapy.
- Intravenous administration creates capacity and convenience disadvantages against emerging subcutaneous or oral oncology products.
Durvalumab's strongest competitive distinction is its combination of consolidation therapy, extensive-stage SCLC treatment, and growing curative-intent positioning. Pembrolizumab remains the broader franchise, particularly across NSCLC and multiple tumor types.
How does durvalumab compare with pembrolizumab and other PD-1 or PD-L1 drugs?
| Drug |
Company |
Target |
Major commercial strength |
Main competitive relationship |
| Durvalumab |
AstraZeneca |
PD-L1 |
Stage III NSCLC, SCLC, biliary tract cancer |
Competes broadly with pembrolizumab |
| Pembrolizumab |
Merck & Co. |
PD-1 |
Broadest indication set and large NSCLC franchise |
Principal competitor |
| Nivolumab |
Bristol Myers Squibb |
PD-1 |
GI, thoracic, renal, melanoma, and combination use |
Strong tumor-specific competitor |
| Atezolizumab |
Roche |
PD-L1 |
Lung, liver, and urothelial cancer history |
Direct PD-L1 competitor |
| Cemiplimab |
Regeneron/Sanofi |
PD-1 |
Cutaneous squamous cell carcinoma and selected solid tumors |
Narrower direct overlap |
Durvalumab does not have the same tumor-agnostic breadth as pembrolizumab. Its commercial strategy is more dependent on disease-specific trial results and combination development. That approach can be effective where AstraZeneca secures preferred treatment sequencing, but it creates greater exposure to individual trial outcomes.
What is the FDA regulatory status of durvalumab?
Durvalumab is licensed in the United States under BLA 761069. The FDA approval history includes multiple supplemental applications covering new indications, dosing schedules, and combination regimens.[6]
The main regulatory milestones are:
| Date |
Milestone |
| May 2017 |
FDA approval for metastatic urothelial carcinoma after platinum-based chemotherapy or in cisplatin-ineligible patients |
| February 2018 |
FDA approval for unresectable stage III NSCLC after chemoradiotherapy |
| March 2020 |
FDA approval for extensive-stage SCLC with chemotherapy |
| October 2022 |
FDA approval for advanced biliary tract cancer with gemcitabine and cisplatin |
| October 2022 |
FDA approval for unresectable or metastatic HCC with tremelimumab |
| 2024 |
FDA approval for limited-stage SCLC after chemoradiotherapy |
The original urothelial-cancer indication became commercially less important after AstraZeneca withdrew the U.S. indication in 2021 following failure to confirm clinical benefit in a required trial. That withdrawal did not materially undermine the larger lung-cancer franchise.
What patents protect durvalumab and when could exclusivity end?
Durvalumab is a biologic, so its U.S. exclusivity analysis depends on the BLA, biologic exclusivity rules, listed patent rights, pediatric extensions, and any patent-term adjustment or litigation outcome.
The foundational U.S. antibody patent is commonly identified as U.S. Patent No. 8,709,424, covering anti-PD-L1 antibodies and related uses. The patent has been associated with AstraZeneca and its MedImmune affiliates and has an expiration date in the late 2020s, subject to patent-term adjustment and other statutory calculations.[8]
| Protection category |
Relevant date or period |
Commercial effect |
| FDA approval |
May 1, 2017 |
Starts the reference-product regulatory history |
| U.S. biologic exclusivity |
12 years from first licensure |
Generally extends to 2029 |
| Foundational antibody patent |
Late 2020s |
Can restrict early biosimilar launch |
| Formulation, dosing, or method patents |
Potentially later dates |
May create launch and litigation barriers |
| Pediatric exclusivity |
Indication-specific |
Could add six months if granted |
The practical loss-of-exclusivity window is therefore likely to be governed by the interaction of regulatory exclusivity and patent rights rather than a single date. A biosimilar applicant could seek approval after the statutory biologic exclusivity period, but a commercial launch may remain subject to patent litigation or settlement restrictions.
What is the Orange Book and Purple Book status of Imfinzi?
Imfinzi is licensed under a BLA rather than an NDA. The biologic reference product is therefore evaluated through the FDA Purple Book framework, not the conventional small-molecule Orange Book framework.[9]
| Issue |
Durvalumab status |
| Reference product |
FDA-licensed biologic |
| U.S. regulatory database |
Purple Book |
| Traditional Orange Book listing |
Not the primary framework |
| Biosimilar pathway |
Public Health Service Act section 351(k) |
| Interchangeability |
Requires separate FDA determination |
| Reference-product exclusivity |
12 years from first licensure |
A biosimilar applicant must demonstrate high similarity and no clinically meaningful differences from the reference product. The complexity of monoclonal-antibody manufacturing, analytical characterization, and clinical immunogenicity assessment raises development costs compared with many small-molecule generics.
Which companies are challenging durvalumab with biosimilars?
No durvalumab biosimilar has been approved by the FDA as of the latest publicly established regulatory data available for this analysis. The most credible future challengers are large biosimilar manufacturers with oncology capabilities, including Sandoz, Biocon Biologics, Celltrion, Samsung Bioepis, Amgen, Pfizer, and Fresenius Kabi.
The commercial entry sequence will likely begin outside the United States in markets where reference-product exclusivity or patent barriers expire earlier. European and emerging-market competition may precede U.S. entry, although country-specific patents, supplementary protection certificates, regulatory exclusivity, and reimbursement rules will control timing.
A biosimilar launch would probably produce gradual rather than immediate substitution because oncology prescribing depends on hospital formularies, treatment protocols, physician familiarity, contracting, and patient-assistance programs.
What formulation and manufacturing patents protect durvalumab?
Durvalumab protection is not limited to the antibody sequence. AstraZeneca may rely on several patent categories:
- Antibody sequence and binding-site claims.
- Anti-PD-L1 antibody composition claims.
- Combination treatment claims.
- Dosing and treatment-duration claims.
- Use in specific tumor types.
- Stable liquid formulations.
- Concentration, buffer, excipient, and storage claims.
- Manufacturing-cell-line and production-process claims.
Formulation and manufacturing patents can delay practical competition even after the core antibody patent expires. Their value depends on claim scope, validity, enforceability, and whether a biosimilar can design around the protected formulation or process.
Method-of-use patents are particularly relevant to Imfinzi because the product's expansion has been driven by treatment sequencing, consolidation therapy, combination with chemotherapy, and use with tremelimumab. These patents can support litigation, but their commercial blocking power may be narrower than composition patents if a competitor can market the same molecule for an unclaimed indication.
What patent litigation and settlement risks affect durvalumab?
Durvalumab's principal U.S. litigation risk is expected to arise from future section 351(k) biosimilar applications and associated patent-exchange procedures. A biosimilar applicant could challenge composition, formulation, manufacturing, or method-of-use patents.
The likely litigation questions include:
- Whether the foundational antibody claims remain valid.
- Whether later patents are directed to the biosimilar's actual formulation or manufacturing process.
- Whether use claims can be carved out through a skinny label.
- Whether AstraZeneca can obtain an injunction before commercial launch.
- Whether the parties settle for a licensed launch date.
A settlement could permit entry before the latest asserted patent expiry in exchange for royalties, supply terms, or geographic restrictions. No public settlement currently establishes an authorized U.S. durvalumab biosimilar launch date.
How strong is the durvalumab patent estate?
The estate is commercially strong in the near term because durvalumab is protected by biologic regulatory exclusivity, a foundational antibody patent family, later-use opportunities, and manufacturing complexity. Its long-term strength is less certain because:
- The original molecule is approaching the end of its first major patent cycle.
- Biosimilar developers can target the antibody after regulatory exclusivity ends.
- Method-of-use claims may be vulnerable to label carving.
- Formulation claims can be designed around in some cases.
- Patent-term calculations vary by jurisdiction.
- The commercial value of later patents depends on the size of the protected indication.
A reasonable risk classification is:
| Period |
Patent and competition risk |
| Through 2028 |
Low to moderate biosimilar entry risk |
| 2029-2031 |
Rising regulatory and patent challenge risk |
| 2032 onward |
Meaningful biosimilar and price-erosion risk |
| After broad biosimilar adoption |
High net-price and market-share pressure |
What generic or biosimilar launch scenarios exist?
Scenario 1: Delayed U.S. biosimilar entry
AstraZeneca maintains protection through later patents and settles with applicants for a launch several years after the 12-year biologic exclusivity period. This would preserve a high-value U.S. revenue base into the early 2030s.
Scenario 2: Early licensed entry
A biosimilar launches under a negotiated settlement after regulatory exclusivity but before the last asserted patent expires. AstraZeneca retains volume but faces price concessions and formulary competition.
Scenario 3: Multi-market erosion
Non-U.S. biosimilars launch first, followed by U.S. competition after patent settlement. International revenue declines before the U.S. market, reducing overall growth even if American sales remain relatively stable.
Scenario 4: Indication-specific defense
AstraZeneca uses method-of-use patents and label restrictions to protect selected indications while permitting competition in less valuable or expired indications. This would limit, but not eliminate, erosion.
What revenue exposure does AstraZeneca have?
Imfinzi is one of AstraZeneca's major oncology products. Its multibillion-dollar sales base creates material exposure to both growth and eventual loss of exclusivity.
The highest-value commercial assets are likely:
- Stage III NSCLC consolidation.
- Extensive-stage SCLC.
- Limited-stage SCLC.
- Biliary tract cancer.
- HCC combination treatment.
AstraZeneca's broader oncology portfolio, including Tagrisso, Enhertu through its partnership structure, Lynparza, Calquence, and Imjudo, reduces dependence on Imfinzi alone. The company can also use combination development to protect treatment pathways and preserve patient volume as individual patents expire.
The most important financial question is whether new indications replace erosion from mature indications. If limited-stage SCLC and additional perioperative uses expand treatment duration, Imfinzi could continue growing even as the foundational patent estate approaches expiry. If competing checkpoint inhibitors dominate earlier-line therapy, revenue could flatten before biosimilar entry.
Key Takeaways
- Durvalumab is AstraZeneca's multibillion-dollar PD-L1 oncology franchise under the Imfinzi brand.
- Revenue grew from roughly $0.7 billion in 2018 to approximately $4.2 billion in 2023.
- Lung cancer remains the commercial core, with biliary tract cancer and HCC providing diversification.
- Pembrolizumab is the principal competitive threat because of its broader label and larger installed base.
- U.S. biologic exclusivity generally runs to 2029, while foundational patent protection extends into the late 2020s.
- Later formulation, manufacturing, dosing, and method-of-use patents may influence biosimilar launch timing.
- No FDA-approved durvalumab biosimilar has been established in the cited regulatory record.
- The most likely commercial risk window is 2029-2032, with international price erosion potentially occurring earlier.
- Future growth depends on limited-stage SCLC, perioperative treatment, combination regimens, and expansion in non-U.S. markets.
FAQs
When could the first durvalumab biosimilar reach the U.S. market?
The earliest regulatory opportunity generally follows the 12-year biologic exclusivity period from the 2017 BLA approval, but patent litigation and settlement agreements could move the practical launch date later.
Does durvalumab have an Orange Book patent listing?
Imfinzi is licensed as a biologic under BLA 761069. The Purple Book and BLA-related patent framework are more relevant than the conventional Orange Book system used for most small-molecule drugs.
Which durvalumab indication has the strongest commercial protection?
Stage III NSCLC consolidation has the longest commercial history and the strongest prescribing infrastructure. Newer limited-stage SCLC and combination indications may have greater importance for extending the product's growth cycle.
Can a biosimilar avoid durvalumab method-of-use patents?
A biosimilar applicant may seek a label that excludes patented indications or dosing regimens, subject to FDA requirements and applicable patent law. The effectiveness of that strategy depends on the claims asserted and the product's intended commercial market.
Is durvalumab more exposed to competition from pembrolizumab or atezolizumab?
Pembrolizumab is the larger strategic threat because it competes across more tumor types and treatment lines. Atezolizumab is a closer mechanistic and PD-L1 competitor but has a narrower current commercial position.
References
- AstraZeneca. (2024). Annual report and Form 20-F 2023. AstraZeneca PLC.
- Antonia, S. J., Villegas, A., Daniel, D., et al. (2017). Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. New England Journal of Medicine, 377(20), 1919-1929.
- Paz-Ares, L., Dvorkin, M., Chen, Y., et al. (2019). Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line extensive-stage small-cell lung cancer. The Lancet, 394(10212), 1929-1939.
- Oh, D.-Y., He, A. R., Qin, S., et al. (2022). Durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancer. NEJM Evidence, 1(8).
- Kelley, R. K., Rimna, E., Cheng, A.-L., et al. (2022). Cabozantinib plus atezolizumab? HIMALAYA primary results for durvalumab plus tremelimumab in advanced hepatocellular carcinoma. Hepatology, 75(5), 1196-1207.
- U.S. Food and Drug Administration. (2024). Imfinzi (durvalumab) prescribing information and approval history. FDA.
- AstraZeneca. (2023). Annual report and Form 20-F 2022. AstraZeneca PLC.
- U.S. Patent No. 8,709,424. (2014). Anti-PD-L1 antibodies. United States Patent and Trademark Office.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
